---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040608"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:12:19.579578+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec

## Summary
- Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.
- Cash $652.2M (down from $720.8M); sufficient to fund operations into 2026.
- Last patient enrolled in XEN1101 Phase 2 X-NOVA MDD trial; topline data expected late Nov to mid-Dec 2023.
- Phase 3 epilepsy trials X-TOLE2/3 and X-ACKT continue; partnered NBI-921352 Phase 2 data expected Q4 2023.
- Webinar on MDD mechanism and X-NOVA design scheduled for mid-September.

## SEC filing metadata
- accession: 0000950170-23-040608
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/0000950170-23-040608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/xene-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040608
- JSON: https://secwatch.observer/filing/0000950170-23-040608.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040608.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for three and six months ended June 30, 2023.
  - Period: three and six months ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, Xenon Pharmaceuticals Inc. (the "Company") announced via press release the Company's financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/0000950170-23-040608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.